Phase 3 Readout

TENX: Phase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertens

Name: Phase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertens
Start: 2028-10-30
End: 2028-10-30

October 30, 2028 · levosimendan. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: October 30, 2028
Company: TENAX THERAPEUTICS, INC. (TENX)
Drug: levosimendan

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertens

October 30, 2028

TENX overview →

Company: TENAX THERAPEUTICS, INC. (TENX)
Drug: levosimendan
Indication: Pulmonary Hypertension